CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Bard Biopsy Systems is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Bard Biopsy Systems
1625 West. 3rd St.
Phone: (800) 321-4254p:800 321-4254 Tempe, AZ  85281  United States Fax: (800) 440-5376f:800 440-5376

This company ceased filing statements with the SEC on 7/16/2010.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Bard Biopsy Systems, formerly known as SenoRx, Inc., develops, manufactures and sells medical devices that are used in the diagnosis and treatment of breast cancer. The Company’s initial product focus has been biopsy systems and breast tissue markers. The EnCor system, its flagship product for use in breast biopsy procedures, is a minimally invasive vacuum-assisted breast biopsy system. EnCor allows users to obtain multiple biopsy samples with a single probe insertion. EnCor also incorporates programmability, which allows the user to select automated cutting patterns, tissue density, number of samples and to deliver anesthetic.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/201012/31/2009YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer, Chief Operating Officer, Director John T.Buhler 49 3/15/2010 5/1/2008
Chief Financial Officer, Vice President - Finance Kevin J.Cousins 55 3/1/2002 3/1/2002
Senior Vice President, Chief Technology Officer PaulLubock 54 4/1/2009 10/1/1999
6 additional Officers and Directors records available in full report.

Business Names
Business Name
SENO
SENORX INC
SenoRx, Inc.

General Information
Stock Exchange: NASD
Federal Tax Id: 330787406
Fax Number: (800) 440-5376


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023